GEN reports the recommendation against follows an EMA action in April after XBiotech informed the EMA of several outstanding issues, yet to be addressed.
Here’s what you should know.
1. The committee said it would re-exam the drug and would promptly notify the EMA of its intent to do so if XBiotech resubmits the drug.
2. In a phase III study with EMA’s Scientific Advisor Group, XBiotech said the drug improved response rate in 76 percent of patients.
3. In a separate phase III study determining overall survival rate, an independent data monitoring committee recommend the study continue unmodified.
More articles on gastroenterology:
Underwater colonoscopy more effective than air insufflation — 5 insights
Variations in billing for colonoscopies leave patients footing the bill — Unclear pricing practices cause confusion, create debt
4 things to know about the AGA’s new President Dr. Sheila Crowe
